Revista espanola de cardiologia最新文献

英文中文

Ecocardiografía transtorácica previa al procedimiento para predecir los resultados de la reparación percutánea de borde a borde en la insuficiencia mitral primaria crónica 术前经胸超声心动图预测慢性原发性二尖瓣反流经皮边缘对边缘修补术的疗效

IF 5.9 2区医学 Q2 Medicine

Revista espanola de cardiologia

Pub Date : 2024-08-01 DOI: 10.1016/j.recesp.2023.12.001

Introduction and objectives

Limited data exist on the prognostic usefulness of transthoracic echocardiography preceding MitraClip for chronic primary mitral regurgitation (MR). We evaluated the predictive ability of transthoracic echocardiography in this setting.

Methods

A total of 410 patients (median age, 83 years, 60.7% males) were included in the study. The primary outcome was the 1-year composite of all-cause mortality or heart failure hospitalization. Secondary endpoints encompassed individual elements of the primary outcome, the persistence of significant functional impairment or above-moderate MR at 1 year, and above-mild MR at 1-month.

Results

The only parameter associated with the risk of the primary outcome was a ventricular end systolic diameter index of ≥ 2.1 cm/m2, corresponding to the cohort's 4 th quartile (HR, 2.44; 95%CI, 1.09-4.68; P = .022). Concurrently, higher left atrial volume index (LAVi) and a mid-diastolic medial-lateral mitral annular diameter (MAD) equal to or above the cohort's median of 32.2 mm were linked to a higher probability of death and heart failure hospitalization, respectively. LAVi of ≥ 60 mL/m2, above-mild mitral annular calcification, and above-moderate tricuspid regurgitation conferred higher odds of functional class III-IV or above-moderate MR persistence. All variables except LAVi and MAD, as well as indexed mid-diastolic medial-lateral MAD of ≥ 20.2 mm/m2 and mitral effective regurgitant orifice area of ≥ 0.40 cm2, were associated with greater-than-mild MR at 1 month.

Conclusions

Preprocedural increased indexed left heart dimensions, mainly left ventricular end-systolic diameter index, MAD, mitral annular calcification, mitral effective regurgitant orifice area, and tricuspid regurgitation mark a less favorable course post-MitraClip for chronic primary MR.

导言和目的关于慢性原发性二尖瓣反流（MR）的 MitraClip 前经胸超声心动图的预后作用的数据有限。我们评估了经胸超声心动图在这种情况下的预测能力。研究共纳入 410 名患者（中位年龄 83 岁，60.7% 为男性）。主要结果是全因死亡率或心力衰竭住院治疗的 1 年综合结果。结果与主要结局风险相关的唯一参数是心室收缩末期直径指数≥2.1 cm/m2，相当于队列的第4四分位数（HR，2.44；95%CI，1.09-4.68；P = .022）。同时，较高的左心房容积指数（LAVi）和二尖瓣环舒张中期内外侧直径（MAD）等于或大于队列中位数（32.2 mm）分别与较高的死亡和心衰住院概率有关。LAVi≥ 60 mL/m2、轻度以上二尖瓣环钙化和中度以上三尖瓣反流导致功能分级 III-IV 级或中度以上 MR 持续存在的几率更高。除 LAVi 和 MAD 外，所有变量以及指数化舒张中期内外侧 MAD ≥ 20.2 mm/m2 和二尖瓣有效反流孔面积 ≥ 0.40 cm2 都与 1 个月时的轻度以上 MR 相关。结论术前增加的左心指数尺寸，主要是左心室收缩末期直径指数、MAD、二尖瓣瓣环钙化、二尖瓣有效反流孔面积和三尖瓣反流，标志着MitraClip术后慢性原发性MR的预后较差。

{"title":"Ecocardiografía transtorácica previa al procedimiento para predecir los resultados de la reparación percutánea de borde a borde en la insuficiencia mitral primaria crónica","authors":"","doi":"10.1016/j.recesp.2023.12.001","DOIUrl":"10.1016/j.recesp.2023.12.001","url":null,"abstract":"<div><h3>Introduction and objectives</h3><p>Limited data exist on the prognostic usefulness of transthoracic echocardiography preceding MitraClip for chronic primary mitral regurgitation (MR). We evaluated the predictive ability of transthoracic echocardiography in this setting.</p></div><div><h3>Methods</h3><p>A total of 410 patients (median age, 83 years, 60.7% males) were included in the study. The primary outcome was the 1-year composite of all-cause mortality or heart failure hospitalization. Secondary endpoints encompassed individual elements of the primary outcome, the persistence of significant functional impairment or above-moderate MR at 1 year, and above-mild MR at 1-month.</p></div><div><h3>Results</h3><p>The only parameter associated with the risk of the primary outcome was a ventricular end systolic diameter index of ≥ 2.1cm/m2, corresponding to the cohort's 4th quartile (HR, 2.44; 95%CI, 1.09-4.68; P=.022). Concurrently, higher left atrial volume index (LAVi) and a mid-diastolic medial-lateral mitral annular diameter (MAD) equal to or above the cohort's median of 32.2 mm were linked to a higher probability of death and heart failure hospitalization, respectively. LAVi of ≥ 60 mL/m2, above-mild mitral annular calcification, and above-moderate tricuspid regurgitation conferred higher odds of functional class III-IV or above-moderate MR persistence. All variables except LAVi and MAD, as well as indexed mid-diastolic medial-lateral MAD of ≥ 20.2 mm/m2 and mitral effective regurgitant orifice area of ≥ 0.40cm2, were associated with greater-than-mild MR at 1 month.</p></div><div><h3>Conclusions</h3><p>Preprocedural increased indexed left heart dimensions, mainly left ventricular end-systolic diameter index, MAD, mitral annular calcification, mitral effective regurgitant orifice area, and tricuspid regurgitation mark a less favorable course post-MitraClip for chronic primary MR.</p></div>","PeriodicalId":21299,"journal":{"name":"Revista espanola de cardiologia","volume":"77 8","pages":"Pages 621-631"},"PeriodicalIF":5.9,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140276800","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Registro español de marcapasos. XXI informe oficial de la Asociación del Ritmo Cardiaco de la Sociedad Española de Cardiología (2023) 西班牙起搏器登记处。西班牙心脏病学会心律协会第二十一期正式报告（2023 年）。

IF 5.9 2区医学 Q2 Medicine

Revista espanola de cardiologia

Pub Date : 2024-07-24 DOI: 10.1016/j.recesp.2024.07.010

Manuel Molina-Lerma , Rocío Cózar-León , Francisco Javier García-Fernández , David Calvo

Introduction

Data on implants of cardiac pacing systems in Spain in 2023 are presented.

Methods

The registry is based on the information provided by centers to the recording platform of the Heart Rhythm Association after device implantations, through Cardiodispositivos, the online platform of the National Registry. Other information sources include: a) data transfers from the manufacturing and marketing industry; b) the European pacemaker patient card; and c) local databases submitted by the implanting centers.

Results

In 2023, 112 hospitals participated in the registry (30 more than in 2022). A total of 24 343 device implantations were reported (48.1% more than in 2022) compared with 45 120 reported by Eucomed (European Confederation of Medical Suppliers Associations). Of these, 1646 were cardiac resynchronization therapy pacemakers. The devices showing the largest increases were leadless pacemakers, with 963 devices implanted, representing an 18.1% increase over 2022. The most frequent indication was atrioventricular block followed, for the first time, by atrial tachyarrhythmia with slow ventricular response. The number of devices included in remote monitoring also increased (cardiac resynchronization therapy defibrillators, 71%; cardiac resynchronization therapy pacemakers, 63%; and conventional pacemakers, 28%), although more moderately.

Conclusions

In 2023, there was an increase in the number of institutions participating in the registry. The reporting of device implantations rose by 48.1%, and the implantation of leadless pacemakers grew by 18.1%. Remote monitoring also experienced modest growth compared with previous years.

导言：本文介绍了 2023 年西班牙心脏起搏系统的植入数据。方法：该登记册基于各中心在植入设备后通过国家登记册在线平台 Cardiodispositivos 向心脏节律协会记录平台提供的信息。其他信息来源包括：a）来自制造和营销行业的数据传输；b）欧洲起搏器患者卡；c）植入中心提交的本地数据库。共报告了 24 343 例设备植入（比 2022 年增加 48.1%），而欧洲医疗供应商协会联合会（Eucomed）报告的植入数量为 45 120 例。其中，1646 台为心脏再同步治疗起搏器。增幅最大的设备是无引线起搏器，共植入 963 台，比 2022 年增长了 18.1%。最常见的适应症是房室传导阻滞，其次是伴有缓慢心室反应的房性快速性心律失常，这还是第一次。纳入远程监测的设备数量也有所增加（心脏再同步治疗除颤器，71%；心脏再同步治疗起搏器，63%；传统起搏器，28%），但增幅不大。设备植入报告增加了 48.1%，无导联起搏器植入增加了 18.1%。与前几年相比，远程监测也有小幅增长。

{"title":"Registro español de marcapasos. XXI informe oficial de la Asociación del Ritmo Cardiaco de la Sociedad Española de Cardiología (2023)","authors":"Manuel Molina-Lerma , Rocío Cózar-León , Francisco Javier García-Fernández , David Calvo","doi":"10.1016/j.recesp.2024.07.010","DOIUrl":"10.1016/j.recesp.2024.07.010","url":null,"abstract":"<div><h3>Introduction</h3><div>Data on implants of cardiac pacing systems in Spain in 2023 are presented.</div></div><div><h3>Methods</h3><div>The registry is based on the information provided by centers to the recording platform of the Heart Rhythm Association after device implantations, through Cardiodispositivos, the online platform of the National Registry. Other information sources include: <em>a)</em> data transfers from the manufacturing and marketing industry; <em>b)</em> the European pacemaker patient card; and <em>c)</em> local databases submitted by the implanting centers.</div></div><div><h3>Results</h3><div>In 2023, 112 hospitals participated in the registry (30 more than in 2022). A total of 24 343 device implantations were reported (48.1% more than in 2022) compared with 45 120 reported by Eucomed (European Confederation of Medical Suppliers Associations). Of these, 1646 were cardiac resynchronization therapy pacemakers. The devices showing the largest increases were leadless pacemakers, with 963 devices implanted, representing an 18.1% increase over 2022. The most frequent indication was atrioventricular block followed, for the first time, by atrial tachyarrhythmia with slow ventricular response. The number of devices included in remote monitoring also increased (cardiac resynchronization therapy defibrillators, 71%; cardiac resynchronization therapy pacemakers, 63%; and conventional pacemakers, 28%), although more moderately.</div></div><div><h3>Conclusions</h3><div>In 2023, there was an increase in the number of institutions participating in the registry. The reporting of device implantations rose by 48.1%, and the implantation of leadless pacemakers grew by 18.1%. Remote monitoring also experienced modest growth compared with previous years.</div></div>","PeriodicalId":21299,"journal":{"name":"Revista espanola de cardiologia","volume":"77 11","pages":"Pages 947-956"},"PeriodicalIF":5.9,"publicationDate":"2024-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141850133","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Registro español de hemodinámica y cardiología intervencionista. XXXIII informe oficial de la Asociación de Cardiología Intervencionista de la Sociedad Española de Cardiología (1990–2023) 西班牙血液动力学和介入心脏病学登记处。西班牙心脏病学会介入心脏病学协会第三十三次正式报告（1990-2023 年）。

IF 5.9 2区医学 Q2 Medicine

Revista espanola de cardiologia

Pub Date : 2024-07-17 DOI: 10.1016/j.recesp.2024.07.005

Teresa Bastante , Dabit Arzamendi , Javier Martín-Moreiras , Ana Belén Cid Álvarez

Introduction and objectives

This article presents the 2023 activity report of the Interventional Cardiology Association of the Spanish Society of Cardiology (ACI-SEC).

Methods

All interventional cardiology laboratories in Spain were invited to participate in an online survey. Data analysis was carried out by an external company and subsequently reviewed and presented by the members of the ACI-SEC board.

Results

A total of 119 hospitals participated. The number of diagnostic studies decreased by 1.8%, while the number of percutaneous coronary interventions (PCI) showed a slight increase. There was a reduction in the number of stents used and an increase in the use of drug-coated balloons. The use of intracoronary diagnostic techniques remained stable. For the first time, data on PCI guided by intracoronary imaging was reported, showing a 10% usage rate in Spain. Techniques for plaque modification continued to grow. Primary PCI increased, becoming the predominant treatment for myocardial infarction (97%). Noncoronary structural procedures continued their upward trend. Notably, the number of left atrial appendage closures, patent foramen ovale closures, and tricuspid valve interventions grew in 2023. There was also a significant increase in interventions for acute pulmonary embolism.

Conclusions

The 2023 Spanish cardiac catheterization and coronary intervention registry indicates a stabilization in coronary interventions, together with an increase in complexity. There was consistent growth in procedures for both valvular and nonvalvular structural heart diseases.

引言和目的本文介绍了西班牙心脏病学会介入心脏病协会（ACI-SEC）2023 年的活动报告。方法邀请西班牙所有介入心脏病实验室参与在线调查。结果共有 119 家医院参与了调查。诊断研究的数量减少了1.8%，而经皮冠状动脉介入治疗（PCI）的数量略有增加。使用支架的数量有所减少，而使用药物涂层球囊的数量有所增加。冠状动脉内诊断技术的使用保持稳定。首次报告了在冠状动脉内成像引导下进行 PCI 的数据，显示西班牙的使用率为 10%。斑块修饰技术继续增长。初级PCI增加，成为心肌梗死的主要治疗方法（97%）。非冠状动脉结构性手术继续呈上升趋势。值得注意的是，在2023年，左房阑尾闭合术、卵圆孔闭合术和三尖瓣介入术的数量都有所增长。结论 2023 年西班牙心导管和冠状动脉介入治疗登记显示，冠状动脉介入治疗的数量趋于稳定，但复杂程度有所增加。瓣膜和非瓣膜结构性心脏病的手术量持续增长。

{"title":"Registro español de hemodinámica y cardiología intervencionista. XXXIII informe oficial de la Asociación de Cardiología Intervencionista de la Sociedad Española de Cardiología (1990–2023)","authors":"Teresa Bastante , Dabit Arzamendi , Javier Martín-Moreiras , Ana Belén Cid Álvarez","doi":"10.1016/j.recesp.2024.07.005","DOIUrl":"10.1016/j.recesp.2024.07.005","url":null,"abstract":"<div><h3>Introduction and objectives</h3><div>This article presents the 2023 activity report of the Interventional Cardiology Association of the Spanish Society of Cardiology (ACI-SEC).</div></div><div><h3>Methods</h3><div>All interventional cardiology laboratories in Spain were invited to participate in an online survey. Data analysis was carried out by an external company and subsequently reviewed and presented by the members of the ACI-SEC board<em>.</em></div></div><div><h3>Results</h3><div>A total of 119 hospitals participated. The number of diagnostic studies decreased by 1.8%, while the number of percutaneous coronary interventions (PCI) showed a slight increase. There was a reduction in the number of stents used and an increase in the use of drug-coated balloons. The use of intracoronary diagnostic techniques remained stable. For the first time, data on PCI guided by intracoronary imaging was reported, showing a 10% usage rate in Spain. Techniques for plaque modification continued to grow. Primary PCI increased, becoming the predominant treatment for myocardial infarction (97%). Noncoronary structural procedures continued their upward trend. Notably, the number of left atrial appendage closures, patent foramen ovale closures, and tricuspid valve interventions grew in 2023. There was also a significant increase in interventions for acute pulmonary embolism.</div></div><div><h3>Conclusions</h3><div>The 2023 Spanish cardiac catheterization and coronary intervention registry indicates a stabilization in coronary interventions, together with an increase in complexity. There was consistent growth in procedures for both valvular and nonvalvular structural heart diseases.</div></div>","PeriodicalId":21299,"journal":{"name":"Revista espanola de cardiologia","volume":"77 11","pages":"Pages 936-946"},"PeriodicalIF":5.9,"publicationDate":"2024-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141853753","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Rest in PEACE? 安息？

IF 5.9 2区医学 Q2 Medicine

Revista espanola de cardiologia

Pub Date : 2024-07-01 DOI: 10.1016/j.recesp.2024.01.007

Raban V. Jeger, Gregor Fahrni

引用次数: 0

En reconocimiento del origen español del CRISPR/Cas9. Implicaciones para el tratamiento de las cardiopatías familiares. Respuesta 纪念 CRISPR/Cas9 的西班牙起源。对治疗家族性心脏病的意义。回应

IF 5.9 2区医学 Q2 Medicine

Revista espanola de cardiologia

Pub Date : 2024-07-01 DOI: 10.1016/j.recesp.2024.03.014

Alessia Argirò , Jeffrey Ding , Eric Adler

引用次数: 0

PET-TC con [18F]-fluorodesoxiglucosa en amiloidosis sistémica con afección cardiaca 18F]-氟脱氧葡萄糖 PET-CT 在心脏受累的全身性淀粉样变性中的应用

IF 5.9 2区医学 Q2 Medicine

Revista espanola de cardiologia

Pub Date : 2024-07-01 DOI: 10.1016/j.recesp.2023.12.007

Alain García-Olea Jurado , Iria Fernández de la Prieta , Lara Ruiz Gómez

引用次数: 0

Stroke 中风

IF 5.9 2区医学 Q2 Medicine

Revista espanola de cardiologia

Pub Date : 2024-07-01 DOI: 10.1016/j.recesp.2023.09.009

Fernando A. Navarro

引用次数: 0

Semaglutida semanal y objetivos cardiovasculares en pacientes con diabetes mellitus tipo 2 e insuficiencia cardiaca con FAVI reducida 2 型糖尿病合并左心室射血分数降低的心力衰竭患者每周服用一次塞马鲁肽与心血管目标的关系

IF 5.9 2区医学 Q2 Medicine

Revista espanola de cardiologia

Pub Date : 2024-07-01 DOI: 10.1016/j.recesp.2023.12.017

Miguel A. Pérez-Velasco , Alicia Trenas , M. Rosa Bernal-López , María D. García de Lucas , Ricardo Gómez-Huelgas , Luis M. Pérez-Belmonte

引用次数: 0

Leandro Plaza Celemín 莱安德罗-塞莱明广场

IF 5.9 2区医学 Q2 Medicine

Revista espanola de cardiologia

Pub Date : 2024-07-01 DOI: 10.1016/j.recesp.2024.04.006

Miguel Ángel García Fernández , Luis Rodríguez Padial

引用次数: 0

ChatGPT-4 frente a evaluación humana para la revisión por pares en cardiología 心脏病学同行评审的 ChatGPT-4 与人工评估对比

IF 5.9 2区医学 Q2 Medicine

Revista espanola de cardiologia

Pub Date : 2024-07-01 DOI: 10.1016/j.recesp.2024.02.018

Agustín Fernández-Cisnal , Pablo Avanzas , David Filgueiras-Rama , Pablo Garcia-Pavia , Laura Sanchis , Juan Sanchis

引用次数: 0

首页上一页

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Revista espanola de cardiologia

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀